View Older Stories View More Recent Stories
-
CVS Health (CVS) Misses Q3 EPS by 46c, Beats on Revenue
-
CVS Health (CVS) call put ratio 1 call to 1.4 puts with focus on November 8 weekly 55 puts into quarter results
-
CVS Health (CVS) November 8 weekly 55 straddle priced into quarter results
-
CVS Health (CVS) call put ratio 4.5 calls to 1 put with focus on November 8 weekly 53 puts into quarter results
-
The election implications for healthcare technology and distribution stocks - BofA
-
CVS Health (CVS) PT Lowered to $66 at Mizuho
-
Moody's Ratings Reviews CVS's (CVS) Ratings for Downgrade
-
Piper Sandler Reiterates Overweight Rating on CVS Health (CVS)
-
Popular stocks with increasing volume: SMCI COIN TSM BABA CVS OKLO AAL BAC
-
Popular stocks with increasing volume: SMCI COIN TSM BABA CVS OKLO AAL BAC
-
CVS Health (CVS) call put ratio 1.3 calls to 1 put as share price down 8%
-
Stocks expected to have increasing option volume: CVS WBA LW USM BA SPR
-
CVS Health (CVS) -11% on warning, new CEO
-
CVS Health (CVS) provides preliminary guidance for Q3, Adjusted EPS of $1.05 to $1.10, vs $1.70 cons
-
CVS Health (CVS) Appoints David Joyner as CEO
-
CVS to report third-quarter results that will fall short of market expectations- WSJ
-
CVS Health (CVS) Names David Joyner as New Chief Executive- WSJ
-
CVS Health (CVS) introduces SimplePay Health
-
CVS Health (CVS) report explores ongoing transformation of community pharmacy
-
TD Cowen Reiterates Buy Rating on CVS Health (CVS)
-
CVS Health (CVS) call put ratio 4.9 calls to 1 put with focus on October 65 calls, November 1 weekly 69 calls and January 70 calls
-
Barclays Upgrades CVS Health (CVS) to Overweight
-
CVS Health (CVS) call put ratio 1.8 calls to 1 put
-
TD Cowen Upgrades CVS Health (CVS) to Buy
-
Attorney General Ken Paxton Sues Big Pharma Drug Manufacturers and Pharmacy Benefit Managers for Conspiracy That Increased Insulin Prices by 1,000%
-
Morgan Stanley Reiterates Overweight Rating on CVS Health (CVS)
-
Mizuho Reiterates Outperform Rating on CVS Health (CVS)
-
Leerink Partners Reiterates Market Perform Rating on CVS Health (CVS)
-
Evercore ISI Reiterates Outperform Rating on CVS Health (CVS)
-
Glenview Capital Prepares for Activist Push at CVS Health (CVS) - WSJ (earlier)
-
FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices
-
CVS Health (CVS) Declares $0.665 Quarterly Dividend; 4.5% Yield
-
10 most actionable policies if Harris wins & stock implications: Jefferies
-
CVS Health (CVS) Appoints Heidi Capozzi as Chief People Officer
-
TD Cowen Reiterates Hold Rating on CVS Health (CVS)
-
CVS Health (CVS) PT Lowered to $63 at Deutsche Bank
-
Midday movers: Super Micro Computer, Airbnb and Lyft fall; Shopify rises
-
CVS Health (CVS) cuts full-year EPS guidance on continued pressure in the health care benefits unit
-
CVS Health (CVS) Tops Q2 EPS by 10c; cuts profit guidance
-
CVS Health (CVS) call put ratio 1.3 calls to 1 put into quarter results
-
CVS Health (CVS) August 9 weekly 58 straddle priced into quarter results
-
Sunrun (RUN), Other Solar Stocks Decline Following Assassination Attempt on Trump
-
FTC to Sue Drug Managers over Insulin Prices - WSJ
-
TD Cowen Reiterates Hold Rating on CVS Health (CVS)
-
CVS Health (CVS) Trades Lower in Sympathy with Walgreens (WBA)
-
RBC Capital on Walgreens (WBA): 'ongoing consumer weakness and pressure on pharmacy margin'
-
Medicare Advantage Plans Quality Ratings To Be Recalculated - WSJ

